Mylan Laboratories Inc. / Matrix Laboratories Limited

HIV/AIDS (generic antiretroviral APIs)

Disease Overview

This deal is API/manufacturing-focused rather than tied to a single disease. Matrix Laboratories was, at the time of the deal, the world's largest supplier of generic antiretroviral (ARV) active pharmaceutical ingredients used in HIV/AIDS therapy, plus a broad portfolio of generic APIs across cardiovascular, CNS and anti-infective drugs.

Strategic Rationale

Mylan's announced acquisition of a controlling stake in Matrix Laboratories was a vertical integration play rather than a therapeutic-area deal. Matrix was India's second-largest API producer and the largest global supplier of generic ARV APIs, supplying both branded generics players and global HIV/AIDS access programs (PEPFAR, Global Fund). Mylan's primary US generics competitors at the time were Teva, Sandoz (Novartis), Watson and Barr — most of whom relied on third-party Indian API supply. By owning Matrix, Mylan vertically integrated upstream into API manufacturing, gained low-cost Indian operations, and obtained an instant ARV finished-dose-form franchise to compete with Cipla, Ranbaxy and Aurobindo in emerging-market HIV access tenders. The deal was signaled as 'the largest-ever takeover in the Indian pharma industry' at the time and was credited with moving Mylan from #3 US generics player toward #2 globally. It also pre-positioned Mylan for the much larger 2007 Merck KGaA generics acquisition.